Table 1. Clinical characteristics of EC patients treated with ICI categorized by BMI.
A Molecular subtyping was available for 437 patients. B Pre-treatment abdominal CT scans were available for 500 patients. BMI, body mass index; ECOG, Eastern Cooperative Oncology Group; CPNH/TP53abn, copy number-high/TP53abnormal; CNL/NSMP, copy number-low/no specific molecular profile; MSI-H, microsatellite instability high; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue. P values were calculated using Kruskal-Wallis, One-way ANOVA, chi-squared, or Fisher’s exact tests.
| All n=524 | Normal BMI n=128 | Overweight n=163 | Obese n=233 | p value | |
|---|---|---|---|---|---|
| Median age (range) | 67 (30 – 94) | 67 (41 – 89) | 68 (43 – 94) | 66 (30 – 91) | 0.02 |
|
| |||||
| Median BMI, kg/m2 (range) | 29.1 (18.5 – 59.4) | 22.6 (18.5 – 24.9) | 27.3 (25 – 29.9) | 34.7 (30 – 59.4) | <0.0001 |
|
| |||||
| Self-reported race - No (%) | |||||
| • White: | 358 (68) | 84 (66) | 121 (74) | 153 (66) | |
| • Black: | 77 (15) | 14 (11) | 20 (12) | 43 (18) | 0.004 |
| • Asian: | 41 (8) | 16 (13) | 15 (9) | 10 (4) | |
| • Other: | 48 (9) | 14 (11) | 7 (4) | 27 (12) | |
|
| |||||
| Histology – No (%) | |||||
| • Endometroid | 205 (39) | 44 (34) | 60 (37) | 101 (43) | |
| ○ Low grade (1,2) | 131 (25) | 32 (25) | 39 (24) | 60 (26) | |
| ○ High grade (3) | 74 (14) | 12 (9) | 21 (13) | 41 (18) | 0.2 |
| • Serous | 136 (26) | 27 (21) | 50 (31) | 59 (25) | |
| • Mixed/high-grade NOS | 75 (14) | 19 (15) | 22 (13) | 34 (15) | |
| • Carcinosarcoma | 70 (13) | 24 (19) | 20 (12) | 26 (11) | |
| • Clear Cell | 23 (4) | 7 (5) | 8 (5) | 8 (3) | |
| • Un- / Dedifferentiated | 15 (3) | 7 (5) | 3 (2) | 5 (2) | |
|
| |||||
| Checkpoint inhibitor – No (%) | |||||
| • Pembrolizumab: | 423 (81) | 95 (74) | 131 (80) | 197 (85) | |
| • Durvalumab: | 74 (14) | 22 (17) | 26 (16) | 26 (11) | 0.15 |
| • Nivolumab: | 17 (3) | 7 (5) | 5 (3) | 5 (2) | |
| • Other: | 10 (2) | 4 (3) | 1 (1) | 5 (2) | |
|
| |||||
| Combination therapies – No (%) | |||||
| • Lenvatinib/pembrolizumab: | 307 (59) | 71 (55) | 98 (60) | 138 (59) | |
| • Tremelimumab/durvalumab: | 35 (7) | 11 (9) | 12 (7) | 12 (5) | 0.73 |
| • ICI alone: | 172 (33) | 42 (33) | 51 (31) | 79 (34) | |
| • Other combination: | 10 (2) | 4 (3) | 2 (1) | 4 (2) | |
|
| |||||
| ECOG Performance Status– No (%) | |||||
| • 0: | 253 (48) | 66 (52) | 91 (56) | 96 (41) | |
| • 1: | 252 (48) | 58 (45) | 67 (41) | 127 (55) | 0.06 |
| • 2–3 | 19 (4) | 4 (3) | 5 (3) | 10 (4) | |
|
| |||||
| Mean cycles per month – No (SD) | 1.2 (± 0.5) | 1.3 (± 0.5) | 1.2 (± 0.6) | 1.1 (± 0.5) | 0.1 |
|
| |||||
| Stage at diagnosis (1,2 vs 3,4) – No (%) | |||||
| • 1,2: | 203 (39) | 46 (36) | 61 (37) | 96 (41) | 0.57 |
| • 3,4: | 321 (61) | 82 (64) | 102 (63) | 137 (59) | |
|
| |||||
| Previous lines of therapy – No (%) | |||||
| • 0 | 31 (6) | 9 (7) | 11 (7) | 11 (5) | |
| • 1 | 281 (54) | 56 (44) | 90 (55) | 135 (58) | 0.25 |
| • 2 | 141 (27) | 40 (31) | 42 (26) | 59 (25) | |
| • ≥ 3 | 71 (14) | 23 (18) | 20 (12) | 28 (12) | |
|
| |||||
| Previous pelvic radiotherapy – No (%) | |||||
| • Yes | 288 (55) | 65 (51) | 96 (59) | 127 (55) | 0.38 |
| • No | 236 (45) | 63 (49) | 67 (41) | 106 (45) | |
|
| |||||
| Molecular subtype – No (%) A | |||||
| • CN-H/TP53abn | 256 (59) | 66 (58) | 77 (58) | (59) | |
| • MSI-H | 97 (22) | 21 (18) | 25 (19) | 51 (27) | 0.06 |
| • CN-L/NSMP | 81 (19) | 25 (22) | 31 (23) | (13) | |
| • POLE | 3 (0.7) | 2 (2) | 0 (0) | 1 (0.5) | |
|
| |||||
| SAT – No (%) B | |||||
| • Low (≤270 cm2) | 251 (50) | 116 (93) | 102 (65) | 33 (15) | <0.0001 |
| • High (>270 cm2) | 249 (50) | 9 (7) | 54 (35) | 186 (85) | |
|
| |||||
| VAT No (%) B | |||||
| • Low (≤112 cm2) | 251 (50) | 112 (90) | 98 (63) | 41 (19) | <0.0001 |
| • High (>112 cm2) | 249 (50) | 13 (10) | 58 (37) | 178 (81) | |
|
| |||||
| VAT/SAT ratio B (%) | |||||
| • Low (≤0.3723) | 250 (50) | 82 (66) | 80 (51) | 88 (40) | <0.0001 |
| • High (>0.3723) | 250 (50) | 43 (34) | 76 (49) | 131 (60) | |